Sierra Metals Inc. is a diversified Canadian mining company focused on the production and development of precious and base metals from its polymetallic Yauricocha Mine in Peru, and Bolivar and Cusi Mines in Mexico. The Company is focused on increasing production volume and growing mineral resources. Sierra Metals has recently had several new key discoveries and still has many more exciting brownfield exploration opportunities at all three Mines in Peru and Mexico that are within close proximity to the existing mines. Additionally, the Company also has large land packages at all three mines with several prospective regional targets providing longer-term exploration upside and mineral resource growth potential.

The Company’s Common Shares trade on the Toronto Stock Exchange and the Bolsa de Valores de Lima under the symbol “SMT” and on the NYSE American Exchange under the symbol “SMTS”.

Conference presenting at:

Speakers (speaker name, title)

  • Mike McAllister, VP Investor Relations

Capstone Turbine Corporation® is the world’s leading producer of highly efficient, low-emission, resilient microturbine energy systems. Capstone microturbines serve multiple vertical markets worldwide, including natural resources, energy efficiency, renewable energy, critical power supply, transportation and microgrids. Capstone offers a comprehensive product lineup, providing scalable systems focusing on 30 kWs to 10 MWs that operate on a variety of gaseous or liquid fuels and are the ideal solution for today’s distributed power generation needs. To date, Capstone has shipped over 9,000 of these systems into 73 countries logging millions of operating hours.

Capstone is committed to improving the efficiency of energy needs around the world, while simultaneously reducing global emissions of pollutants and greenhouse gases. Capstone’s systems help end users improve their impact on the environment, while still meeting power and reliability needs. To date, Capstone has shipped nearly 10,000 units to 83 countries and in FY20, saved customers an estimated $219 million in annual energy costs and 368,000 tons of carbon.

Not only does Capstone enable customers to reduce CO2 and emissions, Capstone applies the same principals to its own environmental footprint and focuses internally on its environmental risks, energy consumption, waste disposal and carbon footprint. Capstone also strives to foster a corporate culture emphasizing its relationship with employees, customers and suppliers in order to ensure that Capstone’s corporate values are aligned with those of its employees, customers and suppliers.

Conference presenting at:

Speakers (speaker name, title)

  • Darren Jamison, President & Chief Executive Officer

Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first commercial product is the Portable Neuromodulation Stimulator, known as the PoNS device.

The PoNS device is authorized for sale in Canada as a class II, non-implantable, medical device for the short term treatment of gait deficit due to mild and moderate symptoms from multiple sclerosis, and chronic balance deficit due to mild-to-moderate traumatic brain injury. It is commercially available in Canada via a network of 19 authorized neuro-rehabilitation clinics.

In the U.S., Helius recently received FDA Breakthrough Device Designation for its PoNS device and submitted a request for de novo classification and clearance to the FDA in August. The PoNS device is also under premarket review by the Australian Therapeutic Goods Administration.

Conference presenting at:

Speakers (speaker name, title)

  • Dane Andreeff, President and Chief Executive Officer
  • Joyce LaViscount, Chief Financial Officer and Chief Operating Officer
  • Jonathan Sackier, Chief Medical Officer

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is primarily composed of central nervous system (CNS) and immunology product candidates. The immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer and autoimmune diseases. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions.

Conference presenting at:

Speakers (speaker name, title)

  • Seth Lederman, CEO

Silence is developing a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-associated proteins. Silence’s proprietary RNA chemistries and delivery systems are designed to improve the stability of molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. The Company has secured high value research and collaboration agreements with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda.

Conference presenting at:

Speakers (speaker name, title)

  • Rob Quinn, CFO
  • Iain Ross, Executive Chairman
  • Giles Campion, CMO
  • Barbara Rusken, corporate counsel
Skip to content

September 10, 2020 Conference

September 10, 2020 Conference

    JOIN OUR MAILING LIST!

    Interesting in receiving a schedule of our conferences? Subscribe here: